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Abstract
Background: PRDM (PRDI-BF1 and RIZ domain containing) proteins are zinc finger proteins involved in multiple cellular
regulations by acting as epigenetic modifiers. We studied a recently identified PRDM member PRDM5 for its epigenetic
abnormality and tumor suppressive functions in multiple tumorigeneses.
Methodology/Principal Findings: Semi-quantitative RT-PCR showed that PRDM5 was broadly expressed in human normal
tissues, but frequently silenced or downregulated in multiple carcinoma cell lines due to promoter CpG methylation,
including 80% (4/5) nasopharyngeal, 44% (8/18) esophageal, 76% (13/17) gastric, 50% (2/4) cervical, and 25% (3/12)
hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell lines. PRDM5 expression could be
restored by 5-aza-29-deoxycytidine demethylation treatment in silenced cell lines. PRDM5 methylation was frequently
detected by methylation-specific PCR (MSP) in multiple primary tumors, including 93% (43/46) nasopharyngeal, 58% (25/43)
esophageal, 88% (37/42) gastric and 63% (29/46) hepatocellular tumors. PRDM5 was further found a stress-responsive gene,
but its response was impaired when the promoter was methylated. Ectopic PRDM5 expression significantly inhibited tumor
cell clonogenicity, accompanied by the inhibition of TCF/b-catenin-dependent transcription and downregulation of CDK4,
TWIST1 and MDM2 oncogenes, while knocking down of PRDM5 expression lead to increased cell proliferation. ChIP assay
showed that PRDM5 bound to its target gene promoters and suppressed their transcription. An inverse correlation between
the expression of PRDM5 and activated b-catenin was also observed in cell lines.
Conclusions/Significance: PRDM5 functions as a tumor suppressor at least partially through antagonizing aberrant WNT/b-
catenin signaling and oncogene expression. Frequent epigenetic silencing of PRDM5 is involved in multiple tumorigeneses,
which could serve as a tumor biomarker.
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Introduction
Tumor-specific epigenetic silencing of tumor suppressor genes
(TSGs) through promoter CpG methylation and histone modifi-
cation is frequently involved in multiple carcinogenesis [1]. CpG
methylation can also be used as an epigenetic biomarker for novel
TSG identification and tumor diagnosis. A series of TSGs such as
p16, RASSF1A, PCDH10 and RASAL, have been identified with
epigenetic inactivation in multiple cancers, through promoter
CpG methylation [2–4].
PRDM (PRDI-BF1 and RIZ domain containing) proteins
belong to the zinc finger protein family, harboring an evolution-
arily conserved N-terminal PR domain followed by 16 zinc finger
repeats [5]. The PR domain, a characteristic C2-H2 zinc finger
motif, shares high homology with SET (Suvar3–9, Enhancer-of-
zeste, Trithorax) domain that is involved in chromatin-mediated
transcriptional regulation [6]. Thus far, seventeen human PRDM
members have been identified, with several possessing growth
inhibitory functions in tumor cells. PRDM1 (PRDI-BF1 or
BLIMP1) functions as a transcriptional repressor of c-MYC and
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induces cell differentiation and apoptosis [7,8]. PRDM2 (RIZ1) is
the first identified member of methyltransferase family with tumor
suppressive function mediated by its PR domain [9,10]. The long
isoform of PRDM3 (MDS1-EVI1) is commonly mutated in myeloid
leukemia [11]. PRDM4 (PFM1) is located at a tumor suppressor
locus 12q23-q24.1 commonly deleted in ovarian, gastric and
pancreatic cancers [12].
PRDM5 (also known as PFM2) is a recently identified PRDM
member, mapped to a commonly deleted region 4q25-26 [13].
PRDM5 was first identified from an EST database based on its
conserved PR domain at the N-terminus followed by 16 zinc finger
motifs [14]. It acts as a candidate TSG in some tumors [14,15].
Recent reports showed PRDM5 silencing by promoter methylation
in multiple cancers including breast, ovarian, colorectal, gastric,
and hepatocellular tumors. Ectopic expression of PRDM5 leads to
G2/M arrest and apoptosis of tumor cells [14], although its
molecular mechanism is still unclear. PRDM5 is a nuclear protein
involved in the epigenetic regulation of various genes, through
interaction with histone methyltransferase G9A and histone
deacetylase 1 (HDAC1) [16].
Here, we studied the epigenetic abnormality and tumor
suppressive functions of PRDM5 in multiple common tumors
including nasopharyngeal, esophageal, gastric, hepatocellular and
cervical cancers.
Results
Frequent silencing of PRDM5 in multiple tumor cell lines
due to promoter methylation
We first examined PRDM5 expression in a panel of human
normal adult and fetal tissues by semi-quantitative RT-PCR. Results
showed that PRDM5 was broadly expressed in all normal tissues
(Figure 1A). We then checked PRDM5 expression in multiple
carcinoma cell lines. Results revealed that PRDM5 was frequently
downregulated or silenced in cell lines of nasopharyngeal, esopha-
geal, gastric, hepatocellular and cervical carcinomas, but readily
detected in immortalized normal epithelial cell lines (Figure 2).
There is a typical CpG island (CGI) spanning the transcription
start site of PRDM5 (Figure 1B), as predicted by CGI searcher
(http://cpgislands.usc.edu/). We thus analyzed its promoter CpG
methylation in tumor cell lines. Methylation-specific PCR (MSP)
results showed that PRDM5 was frequently methylated in silenced
cell lines, including 80% (4/5) nasopharyngeal, 44% (8/18)
esophageal, 76% (13/17) gastric, 25% (3/12) hepatocellular, and
50% (2/4) cervical carcinoma cell lines (Figure 2, Table 1), with
the exception of only infrequent PRDM5 methylation detected in
lung, colon, ovarian and bladder cancer cell lines (Figure S1). In
contrast, no methylation was observed in immortalized normal
epithelial cell lines (Figure 2, Table 1).
To confirm the MSP results, we further examined PRDM5
promoter methylation by high-resolution bisulfite genomic se-
quencing (BGS) analysis of 43 individual CpG sites within its CGI.
The BGS results were consistent with those of MSP, with all
promoter alleles intensively methylated in silenced cell lines but
rare methylated CpG sites detected in expressing normal cell lines
(Figure 3A). Taken together, these results revealed a strong
correlation between PRDM5 promoter CpG methylation and its
transcriptional silencing in tumor cell lines.
Pharmacologic demethylation restores PRDM5
expression
To determine whether promoter methylation directly contrib-
utes to PRDM5 silencing, several silenced tumor cell lines were
treated with DNA methyltransferase inhibitor 5-aza-29-deoxycy-
tidine (Aza) alone or combined with histone deacetylase inhibitor
trichostatin A (TSA). This pharmacologic demethylation restored
PRDM5 expression in all silenced cell lines, accompanied by the
increase of demethylated promoter alleles (Figure 3B and 3C),
indicating that PRDM5 silencing in tumor cells was directly
mediated by promoter methylation.
PRDM5 is a stress responsive gene but its response is
disrupted by promoter methylation
Analysis of regulatory elements of the PRDM5 promoter by
TFSearch (www.cbrc.jp/research/db/TFSEARCH) revealed two
HSF (heat shock factor) and five Sp1 binding sites (Figure 4A),
suggesting that PRDM5might be a stress-responsive gene. We then
examined its response to environmental stress stimuli. We found
Figure 1. PRDM5 expression profile in normal tissues and the CpG island in its promoter. (A) PRDM5 is broadly expressed in human normal
adult and fetal tissues. Sk, skeleton. (B) PRDM5 promoter contains a typical CpG island. Each CpG site is shown as a vertical bar, MSP and BGS primers
are indicated. Transcription start site is showed by a curved arrow.
doi:10.1371/journal.pone.0027346.g001
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that PRDM5 expression was dramatically induced in HK1 cells
with unmethylated promoter alleles, after exposure to heat shock
or UV irradiation. However, this stress response was significantly
reduced or totally abolished in cell lines with methylated promoter
(C666-1 and CNE2) (Figure 4B). Moreover, ChIP assay showed
significant enrichment of HSF1 binding to PRDM5 promoter after
heat shock treatment of HK1 cells (Figure 4C), suggesting that
PRDM5 is indeed stress-responsive but this response is disrupted
when the promoter is methylated.
PRDM5 is frequently methylated in primary tumors
We next examined PRDM5 methylation in primary tumors.
MSP detected PRDM5 methylation in 93% (43/46) nasopharyn-
geal, 58% (25/43) esophageal, 88% (37/42) gastric and 63% (29/
46) hepatocellular carcinomas. In contrast, only weak methylation
was infrequently detected in normal tissues (2/7 nasopharyngeal
and 3/7 esophageal tissues), while no methylation was detected in
any of the 9 paired normal tissues of HCC (Figure 5A, Table 1).
BGS analysis confirmed the dense methylation of PRDM5 in
primary tumors but not normal tissues (Figure 5B). Moreover,
quantitative RT-PCR analysis revealed that PRDM5 was fre-
quently downregulated in methylated primary NPC tumors when
compared to normal larynx (Figure 6).
PRDM5 inhibits tumor cell growth and proliferation
Frequent silencing of PRDM5 in multiple cancer cell lines and
primary tumors indicated that PRDM5 likely functions as a tumor
suppressor. Thus, we examined the effects of ectopic PRDM5
expression on tumor cell clonogenicity. A mammalian expression
vector encoding full-length PRDM5 was transfected into nasopha-
ryngeal, esophageal and gastric cancer cell lines with completely
methylated and silenced PRDM5 (HONE1, KYSE140 and
MKN28). Ectopic PRDM5 expression dramatically reduced the
colony formation efficiencies of all cell lines in monolayer culture,
as compared to vector controls (down to 18%, 32% and 56%,
respectively, Figure 7A upper panel and 7B). Expression of
PRDM5 in these cell lines was confirmed by RT-PCR and
Western blot (Figure 7A bottom panel). Consistently, knock-down
of endogenous PRDM5 using siRNA in HEK293 cells significantly
increased the cell proliferation rate (Figure 7C), suggesting that
PRDM5 does function as a tumor suppressor.
PRDM5 modulates WNT/b-catenin signaling and
represses oncogene expression
As a zinc finger transcription factor and epigenetic modifier,
PRDM5 should exert its tumor suppressive functions through
modulating cell signaling and gene transcription. We thus analyzed
the effect of PRDM5 expression on cell signaling using the TCF/b-
catenin- (TOPFlash) and Ras/MAPK-ERK- signaling (SRE)
luciferase reporter constructs. Although PRDM5 expression did
not affect SRE luciferase reporter activity (data not shown), it did
significantly inhibit TOPFlash reporter activity, an indicator of
TCF/LEF-dependent transcription, with FOPFlash reporter con-
struct containing mutant TCF/LEF binding sites as a control
(Figure 8A). Moreover, the promoter reporter activity of CCND1, a
WNT/b-catenin downstream target gene, was markedly decreased
Figure 2. Silencing of PRDM5 by promoter methylation. PRDM5 is frequently silenced and methylated in multiple carcinoma cell lines, while
expressed and unmethylated in all immortalized normal epithelial cell lines examined (underlined) with GAPDH as a control. Ca, carcinoma; NPC,
nasopharyngeal carcinoma; ESCC, esophageal squamous cell carcinoma; HCC, hepatocellular carcinoma; M, methylated; U, unmethylated.
doi:10.1371/journal.pone.0027346.g002
Table 1. Summary of PRDM5 methylation in cell lines and
primary tumors.
Samples Promoter methylation (%)
Carcinoma cell lines
Nasopharyngeal 80% (4/5)
Esophageal 44% (8/18)
Gastric 76% (13/17)
Cervical 50% (2/4)
Hepatocellular 25% (3/12)
Colorectal 27% (3/11)
Lung 29% (2/7)
Ovarian 0/2
Bladder 2/3
Primary tumors
Nasopharyngeal Ca 93% (43/46)
Esophageal Ca 58% (25/43)
Gastric Ca 88% (37/42)
Hepatocellular Ca 63% (29/46)
doi:10.1371/journal.pone.0027346.t001
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when PRDM5 was expressed (Figure 8B). We also examined
whether PRDM5 methylation/silencing is correlated with enhanced
WNT/b-catenin signaling in tumor cell lines, and found that the
active form of b-catenin was accumulated in cell lines with
methylated and silenced PRDM5, with significant lower level of
active b-catenin detected in PRDM5-expressing cell lines (Figure 8C).
We further examined the expression changes of multiple
oncogenes and tumor suppressor genes after ectopic PRDM5
expression in both normal and tumor cell lines (HEK293 and
HONE1). Real-time PCR showed that several oncogenes were
dramatically repressed by PRDM5, such as CDK4, TWIST1, and
MDM2 (Figure 9A, Table S1). We further performed ChIP assay,
and found direct binding of PRDM5 to the promoters of CDK4
and TWIST1 (Figure 9B). Moreover, PRDM5 expression resulted
in significant decreased levels of H3K4me3 and acetyl-histone H4
in CDK4 and TWIST1 promoters (Figure 9C), both as active
Figure 3. Pharmacologic demethylation restores PRDM5 expression. (A) High-resolution methylation analysis of PRDM5 promoter by BGS.
Each row of circles represents an individual promoter allele. Filled circle, methylated CpG site; open circle, unmethylated CpG site. (B) Pharmacologic
demethylation by Aza alone or combined with TSA restores PRDM5 expression in methylated and silenced carcinoma cell lines. (C) Detailed BGS
analysis of PRDM5 promoter demethylation in cell lines treated with Aza alone or combined with TSA.
doi:10.1371/journal.pone.0027346.g003
Figure 4. PRDM5 is stress responsive. (A) Transcription factor binding sites in the PRDM5 promoter. Promoter region used for ChIP assay was
indicated. (B) Induction of PRDM5 in response to stresses was disrupted in methylated cell lines, but not in unmethylated ones. Promoter methylation
status was shown at the bottom. M, methylated; U, unmethylated. (C) ChIP assay showed enrichment of HSF1 binding to PRDM5 promoter after heat
shock treatment in HK1 cells. *p,0.05.
doi:10.1371/journal.pone.0027346.g004
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transcription marks. Thus, PRDM5 does exert its tumor
suppressive functions through modulating WNT/ b-catenin
signaling and the expression of multiple oncogenes as an
epigenetic modifier (Figure 10).
Discussion
Identification of TSGs silenced by CpG methylation elucidates
the molecular mechanisms of carcinogenesis and develops
epigenetic biomarkers for cancer detection and prognosis
prediction. In the present study, we showed that PRDM5, an
epigenetic modifier gene, was frequently inactivated by promoter
methylation in multiple common cancers. Ectopic expression of
PRDM5 inhibited tumor cell clonogenicity, at least partially
through antagonizing WNT/b-catenin signaling and oncogene
expression such as CDK4, TWIST1, and MDM2.
Epigenetic silencing of TSGs is critically involved in the onset
and progression of multiple cancers, even preceding genetic
changes during tumorigenesis [17]. CpG methylation of TSG
promoters is a fundamental epigenetic mechanism leading to their
Figure 5. Frequent methylation of PRDM5 in primary tumors. (A) Representative MSP analysis in primary tumors and normal tissues. M,
methylated; U, unmethylated. N, paired adjacent normal tissue; T, tumor. (B) Detailed analysis of PRDM5 methylation in primary tumors by BGS.
doi:10.1371/journal.pone.0027346.g005
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inactivation in tumors [1]. Previous studies showed that PRDM5
silencing was mediated by either DNA methylation or trimethyla-
tion of H3K27 [15], but with limited cell lines and tumors studied.
Here, we systematically studied PRDM5 silencing and methylation
in a large collection of cell lines and primary tumors. Our results
showed that aberrant methylation of PRDM5 was associated with
its inactivation in multiple tumor cell lines and primary tumors,
with the silencing/methylation of PRDM5 in cell lines of gastric
cancer (MKN45) and HCC (huH1, Hep3B and HepG2) consistent
with previous studies [14,15]. Our results demonstrate that tumor-
specific promoter methylation represents the predominant mech-
anism of PRDM5 inactivation, although other mechanisms like
gene micro-deletion or mutations might also exist.
We also found that PRDM5 is a stress-responsive gene, but its
response is impaired when the promoter is methylated. When
inspecting the PRDM5 promoter, we found two predicted HSF
binding sites, with the one at 2390 to 2380 (CGGAAATTTCC)
containing a CpG site. It is likely that methylation of this CpG site
would affect the binding of HSF, leading to the disruption of its
stress response. Thus, epigenetic silencing of PRDM5 could abolish
Figure 6. PRDM5 expression in primary NPC tumors determined
by qRT-PCR. PRDM5 expression level in each sample was normalized
to internal control GAPDH. PRDM5 expression level in each tumor
sample relative to normal larynx is shown, with PRDM5 methylation
status shown at the bottom. M, methylated.
doi:10.1371/journal.pone.0027346.g006
Figure 7. PRDM5 inhibits tumor cell growth and proliferation. (A) Representative colony formation assay of HONE1, KYSE140 and MKN28 cell
lines (upper panel); confirmation of ectopic expression of transfected PRDM5 in these cell lines by RT-PCR and Western blot (bottom panel). (B)
Quantitative analysis of colony formation assay. Data were presented as means6SD of three independent experiments. (C) Knock-down of
endogenous PRDM5 using siRNA in HEK293 cells significantly increased cell proliferation rate as determined by CCK8 assay (left); PRDM5mRNA levels
of HEK293 cells were evaluated by qRT-PCR (right). siCTRL, control siRNA; siPRDM5, PRDM5 siRNA.
doi:10.1371/journal.pone.0027346.g007
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cellular protective response to environmental stresses, contributing
to tumorigenesis.
PRDM5 is a zinc finger protein. As a sequence-specific DNA-
binding transcription factor, PRDM5 functions as a repressor
targeting multiple protein-coding and miRNA genes involved in
cell cycle, signal transduction and protein modification [16].
Although with a PR/SET domain in the N-terminus, PRDM5
itself does not possess histone methyltransferase (HMTase) activity.
Instead, PRDM5 acts as an epigenetic modifier by recruiting
histone-modifying enzymes like HMTase G9A and HDAC1 to
target genes [16]. Our study indicates that if the epigenetic
modifier PRDM5 is inactivated in tumor cells, its repression to
target oncogenes would be released and thereby contributing to
tumor initiation and progression.
Previous report showed that ectopic PRDM5 expression caused
cell cycle G2/M arrest and induced apoptosis in tumor cells [14],
while the molecular mechanisms remain unknown. Recently, the
zebrafish PRDM5 was found to regulate Wnt/b-catenin signaling
at the early stages of zebrafish development [18]. Our results are in
agreement with this study. Aberrant activation of WNT/b-catenin
signaling is frequently involved in cancers, accompanied with
elevated levels of active b-catenin [19]. In addition to genetic
defects, epigenetic silencing of WNT/b-catenin antagonists also
leads to aberrant WNT/b-catenin signaling in tumors [19].
Frequent methylation-mediated silencing of extracellular (SFRPs
and DKKs) [20–22] and cytosolic (APC, AXIN2 and DACT3) [23–
25] WNT antagonists, nuclear proteins (SOX7 and SOX17)
[26,27], and non-transforming WNT families (WNT5A, WNT7A
and WNT9A) occurs in cancers [28–30], indicating that the
epigenetic inactivation of WNT-signaling negative regulators plays
a critical role in tumor pathogenesis. Our finding that ectopic
expression of PRDM5 leads to the inhibition of WNT/b-catenin
signaling in tumor cells, probably through upregulating DKK1,
DKK2, and WNT5A [18], suggests a novel mechanistic link
between PRDM5 and WNT signaling in human tumorigenesis.
PRDM5 also significantly inhibited the promoter activity of
CCND1, a direct downstream target oncogene of WNT/b-catenin
signaling which acts as a mitogenic signal sensor [31,32]. CDK4 is
one of the binding partners of CCND1 and also transcriptionally
downregulated by PRDM5. PRDM5 silencing is also linked to the
accumulation of active b-catenin in tumor cells, which leads to
constitutive activation of WNT/b-catenin signaling.
In summary, we found that PRDM5 was frequently silenced by
promoter methylation in multiple tumors. PRDM5 suppresses
tumor cell growth through antagonizing WNT/b-catenin signal-
ing and suppressing multiple oncogenes expression. The high
incidence of PRDM5 methylation in some carcinomas indicates
that it is a potential epigenetic biomarker for these tumors.
Materials and Methods
Cell lines and tumor samples
A series of tumor cell lines were used, including nasopharyngeal,
esophageal, gastric, hepatocellular, lung, colorectal, and cervical
cell lines [33,34]. Immortalized epithelial cell lines NP69, NE083,
Het-1A, NE1 and NE3 were used as normal controls. Carcinoma
cell lines were maintained in RPMI 1640 (Invitrogen) supple-
mented with 10% fetal bovine serum. Cell lines were purchased
from the American Type Culture Collection (ATCC, Manassas,
VA) or obtained from collaborators. Human normal adult and
fetal tissue RNA samples were purchased commercially (Strata-
gene, La Jolla, CA or Millipore Chemicon, Billerica, MA).
Figure 8. PRDM5 antagonizes WNT/b-catenin signaling. (A) Effects of ectopic PRDM5 expression on WNT/b-catenin signaling were assessed by
TOPFlash luciferase reporter assay, with FOPFlash reporter as a control. (B) Ectopic expression of PRDM5 repressed CCND1 promoter (+ ,2 kb
upstream) activity by as determined dual-luciferase assay. (C) Correlation of active b-catenin expression and PRDM5 methylation/silencing in
carcinoma cell lines. Active b-catenin protein level was determined by Western blot. PRDM5 expression was evaluated by RT-PCR. +, expressed;
-, silenced. PRDM5 promoter methylation was examined by MSP. M, methylated; U, unmethylated.
doi:10.1371/journal.pone.0027346.g008
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Samples of normal nasopharyngeal and esophageal epithelial
tissues from healthy individuals were described previously [33].
Nude mice-passaged undifferentiated NPC tumors from North
Africans, C15, C17 and C18 were also used [34]. DNA samples of
NPC, gastric tumors, esophageal squamous cell carcinomas,
hepatocellular carcinomas (T) and their corresponding surgical
marginal normal tissues (N), were described previously [34].
Pharmacologic demethylation and stress treatments
Cell lines were treated with DNA methyltransferase inhibitor 5-
aza-29-deoxycytidine (Aza) (Sigma, St. Louis, MO) and histone
deacetylase inhibitor Trichostatin A (TSA) as reported previously
[3]. Cells were subjected to heat shock treatment with incubation
at 42oC for 1 hour followed by recovery at 37uC for 2 hours. For
UV treatment, medium was removed and the flask was turned
upside down to face the light source in a UV cross-linker
(Amersham Biosciences, Piscataway, NJ). Cells were irradiated for
a dose of 70 J/m2. After irradiation, fresh medium was added, and
cells were recovered at 37uC for 1 hour and then harvested [33].
Plasmid construction
The full length open reading frame (ORF) of PRDM5 [14] was
subcloned into the NotI and KpnI site of the pcDNA3.1 mammalian
expression vector to generate pcDNA3.1-PRDM5 with sequence
and orientation confirmed.
Semi-quantitative RT-PCR and real-time PCR
Total RNA was extracted from cell lines using TRI reagent.
Reverse transcription (RT) using random hexamer, and RT-PCR
using Go-Taq (Promega, Madison, WI) were performed as
previously, with GAPDH as a control [34]. Primers used were
PRDM5F: 59-CAGGTTCTCCCTGAAGTCCT and PRDM5R:
Figure 10. Proposed model of the tumor suppressive functions
of PRDM5. PRDM5 antagonizes WNT/b-catenin signaling and sup-
presses oncogene expression (CDK4, TWIST1, MDM2, etc), which leads
to tumor suppression.
doi:10.1371/journal.pone.0027346.g010
Figure 9. PRDM5 suppresses multiple oncogenes expression. (A) Suppression of oncogene expression by PRDM5 in HEK293 and HONE1 cells,
evaluated by real-time PCR. (B) ChIP assay in HEK293 cells showed direct association of PRDM5 with CDK4 and TWIST1 promoters. (C) Downregulation
of CDK4 and TWIST1 by PRDM5 expression is accompanied by decreased H3K4me3 and acetyl-histone H4 levels at their promoters, determined by
ChIP assay in HEK293 cells.
doi:10.1371/journal.pone.0027346.g009
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59-TGAGATGGTGCCTCATGAAC. RT-PCR was performed
for 32 cycles for PRDM5, while 23 cycles for GAPDH.
Real-time PCR was performed using SYBR Green master
mixture and an HT7900 system according to the manufactures’
instruction (Applied Biosystems, Foster City, CA). To screen for
PRDM5 modulated target genes, total RNA extracted from
PRDM5 or vector-transfected cells was treated with DNase I, and
reverse transcripted as described previously [34]. Real-time PCR
was performed for 34 selected candidate target genes. For each
gene, the expression level in PRDM5-transfected cells was
normalized to control. Primer sequences were listed in Table S2.
Methylation-specific PCR (MSP) and bisulfite genomic
sequencing (BGS)
Bisulfite modification of DNA, MSP and BGS was performed as
previously described [4]. The bisulfite-treated DNA was amplified
with methylation-specific primer set, PRDM5m1: 59-TTGTTT-
CGGGTTTCGCGTTC, PRDM5m2: 59-ATTCCTACTACGA-
AAACGCG; or unmethylation-specific primer set, PRDM5u11:
59-TAGTTTTGTTTTGGGTTTTGT, PRDM5u2: 59-CCATT-
CCTACTACAAAAACACA. All MSP primers were tested for not
amplifying any unbisulfited genomic DNA to ensure the specificity
of MSP. For BGS, bisulfite-treated DNA was amplified using BGS
primer set, PRDM5BGS3: 59-GTTTGAAAATTTAGAGTTG-
GAT and PRDM5BGS4: 59-ACCAAAATAAAAAAAAAAAA-
CC. The BGS PCR products were TA-cloned into pCR4-TOPO
vector with 4–10 colonies randomly chosen for sequencing.
Chromatin immunoprecipitation (ChIP)
ChIP assay was performed using a commercial kit (17–295,
Upstate) according to manufacturer’s protocol. 1 mg antibody was
used for each ChIP assay, while no-antibody immunoprecipitation
was used as negative control. Input DNA and immunoprecipitated
DNA were purified with QIAamp DNA mini kit (51306, Qiagen).
The enrichment of each target sequence was determined by real-time
PCR. Immunoprecipitated DNA enrichment was normalized to its
input. Antibodies used were HSF1 (4356, Cell Signaling), FLAG M2
(F3165, Sigma), Histone H3K4me3 (ab8580, Abcam), and acetyl-
Histone H4 (06–866, Upstate). Primers used were: PRDM5ChIPF:
59-TGGAAAACCTACTTAGTCCAG and PRDM5ChIPR: 59-G-
AGGCTGATCTGAGATGTTC; CDK4ChIPF: 59-TACACAC-
TGGAAGCAAGCAC and CDK4ChIPR: 59-GGTCTTTCAG-
CCTGTCTGC; TWIST1ChIPF: 59-GGAGGACGAATTGTTA-
GACC and TWIST1ChIPR: 59-GCAGTGTCATTGGCCTGAC.
Colony formation assay
Cells were seeded at 16105 cells/ml and cultured overnight in
12-well plates. Cells were then transfected with pcDNA3.1-
PRDM5 or empty vector using FuGene6 (Roche). Forty-eight
hours post-transfection, cells were collected and seeded in 6-well
plates at an appropriate density with G418 selection (400 mg/ml).
After 2-3 weeks, cells were stained with Gentian Violet with
survived colonies ($50 cells/colony) counted.
siRNA transfection and cell proliferation assay
PRDM5 siRNA and siRNA negative control were obtained from
Invitrogen. siRNAs were transfected using Lipofectamine 2000
(Invitrogen) according to manufacturer’s protocol. Twenty-four
hours after transfection, cells were collected and seeded in 96-well
plates (103 cells per well). Cell proliferation rates were determined
at indicated time points using Cell Counting Kit-8 (Dojindo,
Rockville, MD). Triplicates for each sample were performed.
Dual-luciferase reporter assay
Luciferase reporter construct of CCND1 promoter (+ ,2 kb
upstream of transcription start site), or TOPFlash reporter
containing 4xTCF-binding sites (kind gift from Dr. Christof
Niehrs, German Cancer Research Center (DKFZ)), or FOPFlash
reporter containing mutant TCF/LEF binding sites (kind gift
from Dr. Jin Dong-Yan, University of Hong Kong) was co-
transfected with either pcDNA3.1-PRDM5 or empty vector,
together with an internal control Renilla luciferase reporter pRL-
CMV vector using FuGene6 [35]. Forty-eight hours after
transfection, cells were harvested and analyzed by the dual-
luciferase assay kit (Promega, Madison, WI). Each experiment
was repeated for three times. Statistical analysis was carried out
by Student’s t-test, p,0.05 was considered as statistically
significant difference.
Western blot
Cell pellets were incubated in lysis buffer (50 mmol/L Tris-
HCl, pH 8.0; 150 mmol/L NaCl; 0.5% NP40) for 30 minutes on
ice, followed by centrifugation at 14,000 rpm for 15 minutes at
4uC. Cell lysates were resolved using SDS-PAGE gels and
transferred onto nitrocellulose membranes. Membranes were then
incubated with primary antibodies for 1 hour at room temperature
or overnight at 4uC, followed by incubation with a secondary
antibody at room temperature for 1 hour. Immunoreactive bands
were detected using Western blot Luminol reagent (GE Health-
care Bio-Sciences) according to the manufacturer’s protocol.
Antibody used were FLAG M2 (F3165, Sigma), active b-catenin
(05-665, Upstate) and a-Tubulin (DM1A, Lab Vision).
Supporting Information
Figure S1 PRDM5 downregulation and methylation is rarely
detected in cell lines of lung, colorectal, ovarian and bladder
cancer. Ca, carcinoma; M, methylated; U, unmethylated.
(TIF)
Table S1 Real-time PCR of PRDM5 target genes. Modulation
of multiple genes by PRDM5 expression in HEK293 and HONE1
cells was evaluated by real-time PCR. Data were obtained from
three independent experiments and presented as relative average
ratio. The expression of target genes in PRDM5-transfected cells
were normalized to those in vector controls, GAPDH was used as
internal control. p,0.05 was considered as statistical significance
by Student’s t-test.
(DOC)
Table S2 Primers for target gene screening by real-time PCR
analysis.
(DOC)
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